30 results about "Salmonella Phage" patented technology

The invention relates to a salmonella phage, and in particular to a long-tail wide-host-spectrum salmonella pullorum strongly cracked phage. The salmonella pullorum phage is named as SP4, which is preserved in China General Microbiological Culture Collection on July 27, 2017 with preservation number of CGMCC No.14332. The phage is relatively strong in cracking effect on salmonellae; and the phagecan also reduce a death rate of chicks infected by pullorum disease. The preparation (phage) can be independently used or serve as cocktail; therefore, a phage product source, which is safe, free fromtoxic and side effects and free from residues, is provided for the treatment of infection of chicken-source salmonella, duck-source salmonella, mink-source salmonella, food-source salmonella and pig-source salmonella.

The invention relates to the field of microbes and provides a novel salmonella phage and a composition, a preparation method and application thereof. The novelsalmonella phage is Myoviridaesp. BP-66 with the preservation numberCCTCC NO: M2015146,Myoviridaesp. BP-63 with preservation number CCTCC NO: M2015145, or Chilikevirussp. BP-12 with the preservation number CCTCCNO: M2015141. The novel phage is a strict virulent phage, has high toxicity to host bacteria, has a wider host range and still has high toxicity to the host bacteria at low concentration. The DNA of the phage cannot encode protein possibly causing potential health risks. The novel phage stably survives in a culture solution at room temperature and survive for more than 6 months at the temperature below 4 DEG C. In addition, the phage can be proliferated on pathogenic bacterial hosts, and large-scale industrial production can be achieved. The salmonella phage can provide excellent strain resources for application of phage therapy.

The invention discloses a salmonella bacteriophage and bacteriophage anti-bacterium composition and an application thereof. A bacteriophage is salmonella enteritidis bacteriophage LPSE1 and salmonella typhimurium bacteriophage LPST10, and both the salmonella enteritidis bacteriophage LPSE1 and the salmonella typhimurium bacteriophage LPST10 have excellent inhibiting effect on salmonellas and good tolerance for pH (potential of hydrogen) and temperature. Application examples of the salmonella bacteriophage to food systems verify that the bacteriophage has excellent effect when being used for bacteriostatic agents. The salmonella enteritidis bacteriophage LPSE1 and the salmonella typhimurium bacteriophage LPST10 have synergistic effects after being mixed and have more beneficial inhibiting effect as compared with a single bacteriophage.

The present invention relates to a phage preparation, especially a Salmonella phage preparation and a preparation method thereof, and belongs to the field of bioengineering. According to the present invention, phage with a preservation number of CCTCCNO: M 2014145 adopts Salmonella as host bacteria to ferment so as to prepare the Salmonella phage preparation; the optimal Salmonella phage STP4-a liquid proliferation conditions such as the culture temperature, the time, the pH value, the ion concentration, the rotation speed, the inoculation amount and the like are explored so as to determine the optimal culture conditions, and the progressive enlargement culture is performed to determine the optimal phage preparation conditions; and the preparation can be separately used or used in a compounding manner, can specifically inactivate a variety of salmonella, and provides a safe and no toxic-side effect phage product source for current prevention and control of Salmonella contamination.

The invention relates to the field of microorganisms, and provides a novel salmonella phage, a composition thereof, and a preparation method and application thereof. The novel salmonella phage is a myoviridae BP-66, the preservation number is CCTCC NO: M2015146, the preservation number of the myoviridae BP-63 is CCTCC NO: M2015145, the preservation number of chilikevirus BP-12 is CCTCC NO: M2015141. The novel bacteriophage is a strict virulent bacteriophage, has high toxicity to host bacteria, has a wide host range, and still has high toxicity to the host bacteria at low concentration; the DNAof the phage cannot encode protein that can pose a potential health risk; the bacteriophage stably survive in a culture solution at room temperature, and can live for more than 6 months below 4 DEG C; the bacteriophage can be well proliferated on a non-pathogenic bacterial host; large-scale industrial production can be achieved. The salmonella phage can provide excellent strain resources for theapplication of phage therapy.

The invention discloses a salmonella phage tail receptor binding protein RBP-55 and an application of the salmonella phage tail receptor binding protein RBP-55 in salmonella detection. The amino acid sequence of the salmonella bacteriophage receptor binding protein RBP-55 is SED ID No. 1; the bacteriophage receptor binding protein RBP-55 disclosed by the invention can recognize and bind a receptor on the surface of salmonella, and is coupled with an activated water-soluble carboxyl quantum dot to form a salmonella bacteriophage receptor binding protein-quantum dot conjugate RBP-55-QDs; the probe is a bifunctional detection probe which specifically recognizes and binds salmonella and generates a fluorescence signal. The salmonella rapid fluorescence detection kit is used for qualitative and quantitative detection of a to-be-detected sample, the detection time is about 1 h, and the detection limit reaches 1 CFU / mL. The application range of the phage receptor binding protein in food safety detection is expanded.

The invention relates to the field of food safety, and particularly discloses a broad-spectrum salmonella phage LPSTLL and application. The preservation number of the salmonella phage LPSTLL is CCTCCNO: M 2019049. The salmonella phage LPSTLL is a virulent phage, has a very broad host spectrum and can lyse 13 kinds of serotype salmonellae such as salmonella typhimurium, salmonella enteritidis andsalmonella dublin and lyse a plurality of strains of drug-resistant salmonellae. The invention further discloses bacteriostatic application of the phage as a biological control agent in food storage.The phage particularly can inhibit contamination caused by the proliferation of salmonellae in milk and chicken, and therefore the safety and hygiene of food are ensured.

The invention discloses a broad-spectrum salmonella bacteriophage biological bactericide and an application thereof. The biological bactericide comprises salmonella bacteriophage and an auxiliary agent, wherein the salmonella bacteriophage comprises at least more than three of salmonella bacteriophage PSA-6, pullorosis salmonella bacteriophage PSPu-4-116, salmonella enteritidis phage, salmonella typhimurium phage, salmonlla derby phage or London salmonella bacteriophage, wherein the preservation number of the salmonella enteritidis phage is CCTCC NO:M2014429; the preservation number of the salmonella typhimurium phage is CCTCC NO:M2014433; the preservation number of the salmonlla derby phage is CCTCC NO:M2014431; and the preservation number of the London salmonella bacteriophage is CCTCC NO:M2014432. The biological bactericide is compounded of a plurality of lytic salmonella bacteriophages to serve as an effective germicidal ingredient, so that the sterilization range is greatly expanded and the bactericidal activity is increased.

The invention discloses a salmonella phage LPST144 and antibacterial application of a lyase of the salmonella phage LPST144. The phage is called after Salmonella Typhimurium Bacteriophage LPST144. Thesalmonella phage LPST144 disclosed by the invention and the lyase LysT15 thereof can crack salmonella; through specifically cracking the salmonella by employing the phage and the lyase thereof, the salmonella can be prevented from evolving, and the generation of drug-resistant strains is reduced; both the phage strain disclosed by the invention and the lyase thereof have hydrophilic phases, and spraying solutions or eluents are very easily prepared through the traditional method so as to disinfect environments or utensils; and the phage disclosed by the invention and the lyase thereof are free of toxic or side effects, can serve as food additives and have potential applications in dealing with food contamination.

The invention relates to a preservative for medical foods. The preservative is prepared from, by weight, 1-9 parts of staphylococcus aureus phage powder, 1-9 parts of escherichia coli phage powder, 1-9 parts of Salmonella phage powder, 1-9 parts of shigella phage powder, 1-9 parts of listeria phage powder, 1-9 parts of proteus bacteriophage powder, 1-9 parts of botulinum phage powder and 4-6 partsof an antioxidant. The preservative can specifically inhibit pathogenic bacteria of common contaminated foods, effectively prevent pollution of the medical foods, prevent oxidation of lipids in the medical foods, and be the antibacterial, anti-oxidation, safe and non-toxic side effect preservative for the medical foods.

The invention discloses a salmonella enteritidis phage LPSE28, with the preservation number of CCTCC NO. 2018120. The salmonella enteritidis phage adopts a wide-spectrum type and can perform pyrolysison a drug-resistant strain of salmonella. Through verification, the salmonella enteritidis phage belongs to caudovirales myoviridaeT4-like viruses, and is called after LPSE28. The pH value of the phage LPSE28 is between 4 and 12, and the titer of the phage is stable at 40-60 DEG C. The invention also discloses application of the salmonella enteritidis phage LPSE28 to food. By utilization of the phage provided by the invention, salmonella enteritidis in food, particularly liquid eggs and milk systems can be effectively controlled, and compared with an antibiotic and a chemical preservative, the phage LPSE28 has the characteristics of high specificity, no residues and safety.

The invention discloses a Salmonella phage resistant to antiviral drugs. The preservation number is CGMCC No.21994. After sequencing the whole gene, it is found that it does not have virulence genes and lysogenic genes; the Salmonella phage RDP‑SA‑20032 After being treated at 60°C for 60 minutes, the titer remained at 10 9 pfu / mL, has good tolerance to temperature; in the range of pH 4‑9, cultured at 37 ° C for 1 h, the titer still remains at 10 11 pfu / mL, at pH=12 and pH=2, there are still phages surviving, and the acid-base tolerance range of the phage is wide; the titer stability of the Salmonella phage is good under the coexistence condition of antiviral drugs; The titer is still stable after being dissolved at 4°C for 72 hours, and can withstand higher temperatures. It can be produced by using a conventional spray drying tower to improve production efficiency and reduce production costs.

The invention belongs to the field of biotechnology, and in particular relates to a Salmonella phage with a wide splitting spectrum and its application. The bacteriophage is a potent bacteriophage, has a strong lytic effect on Salmonella, and belongs to the family Long-tailed bacteriophage; the bacteriophage can form large, translucent plaques on solid medium with a halo around it; It can survive under the condition of ℃~70℃; cultured for 12h under the condition of MOI=0.001, its titer is 1.2×10 10 pfu / mL. The Salmonella phage provided by the invention has high titer and good safety, can be used alone or in combination, and has strong lytic activity against Salmonella with multiple serotypes or multiple drug-resistant phenotypes; Products and means of salmonella contamination. The bacteriophage can provide an excellent source of bacteriophage for the development of bacteriophage therapy, has good application and development prospects, and is suitable for popularization and application.

The invention belongs to the field of prevention and control of Salmonella in livestock and poultry breeding of biotechnology, and discloses a Salmonella phage capable of reducing the vertical transmission of Salmonella pullorum and its application. The preservation number of the phage is CCTCC NO: M 2020661. The bacteriophage GSMP2233 fermentation efficiency in the present invention is high, when MOI=0.01, culture 6h titer reaches 8.9x10 10 PFU / ml has a good purification effect on Salmonella pullorum, can effectively reduce the vertical transmission of Salmonella pullorum, and provides a safe, non-toxic and side-effect-free biological control measure for large-scale fermentation and production of Salmonella purification.

The invention discloses a phage composition and its application in preventing and treating chicken oviductitis. The phage composition includes coli phage PD07 and Salmonella phage PYC04; the coli phage PD07 has a preservation number of CGMCC No18865 and was released in 2019. It was deposited in the China General Microorganism Culture Collection and Management Center on November 4; the Salmonella phage PYC04, with the preservation number CGMCC No18867, was preserved in the China General Microbiology Culture Collection and Management Center on November 4, 2019. The phage composition is used as an effective component for preventing and treating chicken salpingitis through the compounding of coliphage PD07 and Salmonella phage PYC04. Compared with a single lytic coliphage, it greatly broadens its bactericidal range and increases its bactericidal activity , can increase the laying rate of laying hens, enhance the physique and disease resistance of laying hens.

The invention provides a lysosome and holin composition for resisting salmonella phage expression, a preparation method thereof and application of the lysosome and holin composition, and belongs to the technical field of bioengineering. The amino acid sequence of lysosome is as shown in SEQ ID NO:1, and the amino acid sequence of holin is as shown in SEQ ID NO:2. The lysosome Lys 2 and the holin Hol 2 for resisting salmonella phage expression have broad-spectrum bactericidal activity, have a relatively good antibacterial effect on various Gram-positive and Gram-negative bacteria, and have an obvious killing effect on salmonellae, and the lysosome Lys 2 has an N-terminal enzyme activity structural domain, and can split beta-1,4-glucosidic bonds, and the holin Hol 2 has a conservative structural domain, can destroy cells, and transfers information to control the lysis time of cells; and the lysosome Lys 2 and the holin Hol 2 can be used for preparing drugs for preventing, inhibiting or treating cell infections, and have popularization and application value in the field of medical treatment and food safety.